You are not logged in.
Openly accessible

Antifungal synergy of theaflavin and epicatechin combinations against Candida albicans

Betts, Jonathan W., Wareham, David W., Haswell, Stephen J. and Kelly, Stephen M. 2013, Antifungal synergy of theaflavin and epicatechin combinations against Candida albicans, Journal of microbiology and biotechnology, vol. 23, no. 9, pp. 1322-1326, doi: 10.4014/jmb.1303.03010.

Attached Files
Name Description MIMEType Size Downloads
haswell-antifungalsynergy-2013.pdf Published version application/pdf 687.01KB 74

Title Antifungal synergy of theaflavin and epicatechin combinations against Candida albicans
Author(s) Betts, Jonathan W.
Wareham, David W.
Haswell, Stephen J.
Kelly, Stephen M.
Journal name Journal of microbiology and biotechnology
Volume number 23
Issue number 9
Start page 1322
End page 1326
Total pages 5
Publisher Korean Society for Microbiology Biotechnology
Place of publication Seoul, Korea
Publication date 2013
ISSN 1017-7825
1738-8872
Keyword(s) Antifungal
Theaflavin
Epicatechin
Synergy
Candida albicans
Summary New antifungal agents are required to compensate for the increase in resistance to standard antifungal agents of Candida albicans, which is an important opportunistic fungal pathogen that causes minor infections in many individuals but very serious infections in those who are immune-compromised. In this study, combinations of theaflavin and epicatechin are investigated as potential antifungal agents and also to establish whether antifungal synergy exists between these two readily accessible and cost-effective polyphenols isolated from black and green tea. The results of disc diffusion assays showed stronger antibacterial activity of theaflavin:epicatechin combinations against C. albicans NCTC 3255 and NCTC 3179, than that of theaflavin alone. Minimum inhibitory concentrations (MICs) of 1,024 μg/ml with theaflavin and 128-256 μg/ml with theaflavin:epicatechin combinations were found. The fractional inhibitory concentration indexes were calculated, and the synergy between theaflavin and epicatechin against both isolates of C. albicans was confirmed. Theaflavin:epicatechin combinations show real potential for future use as a treatment for infections caused by C. albicans.
Language eng
DOI 10.4014/jmb.1303.03010
Field of Research 060101 Analytical Biochemistry
Socio Economic Objective 920507 Women's Health
HERDC Research category C1.1 Refereed article in a scholarly journal
Copyright notice ©2013, Korean Society for Microbiology Biotechnology
Free to Read? Yes
Persistent URL http://hdl.handle.net/10536/DRO/DU:30063525

Document type: Journal Article
Collections: Office of the Deputy Vice-Chancellor Research
Open Access Collection
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 11 times in TR Web of Science
Scopus Citation Count Cited 13 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 215 Abstract Views, 74 File Downloads  -  Detailed Statistics
Created: Fri, 23 May 2014, 09:38:01 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.